Caplin Point Laboratories Limited
₹2,301.70▼ -36.50 (-1.56%)
CAPLIPOINT·NSE·Healthcare
Market Cap
17484.21 Cr
PE Ratio
27.28
Volume
1,32,806
Day High - Low
2361.90 - 2248.10
52W High-Low
2990.00 - 1500.30
₹2,301.70▼ -36.50 (-1.56%)
Market Cap17484.21 Cr
PE Ratio27.28
Volume1,32,806
Day High - Low2361.90 - 2248.10
52W High-Low2990.00 - 1500.30
Caplin Point Laboratories Limited (CAPLIPOINT): company summary
The company's business is improving, with annual revenue rising 12.9% and net profit growing 20.1% year-over-year.
Caplin Point Laboratories Limited (CAPLIPOINT) is a small-cap Healthcare company valued at ₹17,484 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Caplin Point Laboratories Limited last traded at ₹2,301.7, modestly down 1.56% on the day.
- Recent developments
- On 2026-06-30, the company reported its latest quarter results, showing revenue of ₹610 crore and net profit of ₹179 crore, up 19.7% and 18.6% respectively from the same quarter a year earlier. On 2026-05-29, the company announced a dividend of ₹4.00 per share, with an ex-date of 2026-05-29. On 2026-09-18, another dividend of ₹4.00 per share was announced, with an ex-date of 2026-09-18.
- Financial performance
- The company's business is improving, with annual revenue rising 12.9% and net profit growing 20.1% year-over-year. The latest quarter saw revenue increase 19.7% and net profit rise 18.6% compared to the same quarter a year earlier. Net profit margin expanded 1.8 percentage points to 29.7%, while return on equity remained at 17.9%.
- Valuation multiples
- The stock trades at 27.3 times earnings, broadly in line with the Healthcare median of 32.0, 6.30 times book value. It yields 0.3%.
- Things to watch
- The stock is 12.0% below its 52-week high. Foreign institutional holding decreased by 0.40 percentage points in the quarter, while domestic institutional holding increased by 0.35 percentage points. The company's debt to equity ratio remains at 0.00, indicating no leverage.
- Where it stands
- Caplin Point Lab Ltd has shown strong growth in both revenue and net profit over the past year and quarter, with net profit margin expanding. The company's debt to equity ratio remains at 0.00, and the stock is currently 12.0% below its 52-week high. The most significant movement was in the net profit margin, which increased by 1.8 percentage points.
Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
6.9/10
Fair
Fair Value
Sign in to see
ROE
17.88%
Strong
P/E
27.28x
Fair
Debt / Equity
0.00
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
NIFTY 500NIFTY SMALLCAP 250
Day₹2248
₹2362
52W₹1500
₹2990
DocStoX take
Supported by risk (9.4) and growth (8.8), but held back by valuation (2.7). Risk looks strong at 9.4, but that is offset by valuation at 2.7. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence6.9
/10
Fair
Quality
Excellent
ROE 17.9%
Valuation
Expensive
P/E 27.3×
Growth
Strong
Revenue +15.6% 5Y CAGR
Risk
Low risk
D/E 0.00
Momentum
Firm
54% of 52-week range
At a glance
Market Cap
₹17,484 Cr
52W High / Low
₹2990 / ₹1500
Dividend Yield
0.29%
Promoter Holding
70.57%
EPS (TTM)
₹84.36
Book Value
₹471.90
Key highlights
- Low leverage — D/E 0.00
- Healthy net margin (30%)
- Profitable in all of the last 5 years
4 Positives0 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Caplin Point Laboratories Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Caplin Point Laboratories Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Caplin Point Laboratories Limited with peers
Caplin Point Laboratories Limited vs Sun Pharmaceutical Industries LimitedCaplin Point Laboratories Limited vs Divi's Laboratories LimitedCaplin Point Laboratories Limited vs Torrent Pharmaceuticals LimitedCaplin Point Laboratories Limited vs Apollo Hospitals Enterprise LimitedCaplin Point Laboratories Limited vs Zydus Lifesciences LimitedCaplin Point Laboratories Limited vs Laurus Labs Limited
Related tools & concepts
Value Caplin Point Laboratories Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing